PROV to UTILITY 2 HORMONAL PHASE‑ALIGNED SYSTEM
PHASE-ALIGNED NUTRITIONAL MAPPING SYSTEM, COMPOSITIONS, KITS, AND METHODS OF PROVIDING SAME
PROPOSED NONPROVISIONAL UTILITY PATENT APPLICATION — WORKING DRAFT
Basis: uploaded formulation provisional + Figures 1–5 + inventor-supplied nutritional-mapping architecture.
ATTORNEY REVIEW NOTE: Confirm exact priority data, inventorship, written-description/enablement support, and whether later-added mapping language should be pursued here, in a continuation/CIP, or as a separate family.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Patent Application No. [INSERT], filed [INSERT], entitled “HORMONAL PHASE-ALIGNED HORMONE RECEPTOR-POSITIVE-SAFE NUTRACEUTICAL SYSTEM AND METHOD OF PROVIDING SAME.”
FIELD OF THE INVENTION
The disclosure relates to nutritional compositions, systems, kits, and methods for differentiated nutritional support across a plurality of changing female endocrine-associated physiological states. An endocrine-associated state or hormonal pattern is associated with a physiological environment; the environment is translated into nutritional support priorities; the priorities are mapped to functional ingredient categories; and compositionally distinct formulations, doses, timing, or administration schedules are selected for multiple states.
BACKGROUND
Female endocrine physiology changes over time and may be associated with changes in metabolism, energy, recovery, mood, sleep, skin health, nutrient utilization, inflammatory processes, neurological processes, and tissue remodeling. Existing supplements frequently provide substantially the same composition each day or address only one condition or life stage.
The disclosure does not seek to claim a naturally occurring relationship between a hormone and a physiological consequence. It concerns an applied nutritional system: determining one of multiple endocrine-associated physiological states, determining nutritional support priorities associated with that state, selecting functional nutritional categories addressing those priorities, and providing compositionally differentiated formulations across multiple states.
Ingredients may be defined both by identity and by functional nutritional role so that the architecture is not dependent on one named ingredient where another ingredient performs substantially the same nutritional function.
SUMMARY OF THE INVENTION
A method comprises determining a current state from multiple changing female endocrine-associated physiological states; associating the state with a physiological environment; determining nutritional support priorities; selecting functional ingredient categories; and selecting or administering a nutritional composition that differs compositionally from a composition associated with at least one other state.
State determination may use calendar timing, menstrual onset, cycle history, symptoms, user-reported information, historical patterns, biomarkers, wearable-derived information, laboratory measurements, algorithmic inference, hormonal measurements, or combinations thereof. Direct hormone measurement is not required.
The system is not limited to exactly four states or a fixed 28-day cycle. Formulations may differ by ingredient identity, functional category, amount, dose, ratio, concentration, delivery form, timing, frequency, or combinations thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates a representative multi-phase administration schedule. FIG. 2 illustrates a representative phase-associated pod/container. FIG. 3 illustrates a software-gated booster-pod interface. FIG. 4 illustrates representative hormone curves and menstrual-cycle phases. FIG. 5 illustrates representative endocrine signals, physiological environments, biological priorities, and phase-associated nutritional architecture.
DETAILED DESCRIPTION
Applied Nutritional Mapping Architecture
The invention may be represented as: endocrine-associated state or hormonal pattern → associated physiological environment → nutritional or functional support priority → functional ingredient category → differentiated formulation, dose, timing, or administration. This is an applied formulation-design and administration architecture rather than a claim to the natural physiological relationship itself.
State Determination
A user state may be determined without direct hormone testing using calendar timing, menstrual onset, cycle history, symptoms, user-reported information, historical patterns, biomarkers, wearable-derived information, laboratory measurements, algorithmic inference, hormonal measurements, or combinations thereof. A state may be predetermined, inferred, predicted, confirmed, dynamically updated, or manually selected.
Multiple Changing States
The system addresses multiple changing physiological states rather than only a single endocrine condition or life stage. Representative states include menstrual, follicular, ovulatory, and luteal states. Cycle duration may vary and may include regular, irregular, algorithmically predicted, and biomarker-confirmed cycles. The number of states need not be exactly four.
Physiological Environments and Priorities
Representative environments include tissue regeneration, endometrial shedding, immune remodeling, follicular growth, anabolic metabolism, cellular proliferation, connective-tissue synthesis, mitochondrial activation, ovulation-associated remodeling, extracellular-matrix remodeling, oxidative metabolism, cellular resilience, neuroendocrine regulation, metabolic stabilization, physiological recovery, digestive changes, sleep-related changes, and thermoregulatory changes. Each environment is translated into one or more nutritional support priorities.
Functional Ingredient Categories
Functional categories include mineral restoration/balance; hematopoietic/iron; electrolyte/hydration; vitamin/micronutrient; antioxidant/cellular defense; mitochondrial/cellular energy; energy/fatigue; glucose metabolism; lipid metabolism; protein/amino acid; muscle/lean mass; bone; joint/cartilage/tendon/ligament; connective tissue/extracellular matrix; skin; hair/nail; neurotransmitter; cognitive/neurological; mood; relaxation/sleep; stress/neuroendocrine; digestive; microbiome; intestinal barrier; bowel regularity/motility; immune; inflammatory response; metabolic; thermoregulatory; cardiovascular; endothelial/microcirculatory; hepatic metabolism; methylation/one-carbon; cellular repair/tissue recovery; DNA synthesis/cellular proliferation; membrane/cellular structure; hormone-synthesis cofactor/endocrine-function support without necessarily providing hormones or hormone-mimetic compounds; hormone metabolism/clearance; reproductive tissue; menstrual-loss recovery; follicular-development; ovulatory physiological; luteal physiological; fluid balance; appetite/satiety; nutrient absorption/bioavailability; enzyme/metabolic cofactor; oxidative metabolism; physical performance/recovery; and circadian rhythm.
Functional Equivalents
A functional category may be satisfied by different ingredients, forms, sources, salts, chelates, extracts, strains, compounds, or combinations thereof that provide substantially the same nutritional function for the relevant state. Specific ingredients are representative embodiments rather than the sole definition of a functional category.
Representative Four-State Mapping
A menstrual-associated state may emphasize mineral restoration, hematopoietic support, inflammatory-response support, recovery, and micronutrient repletion. A follicular-associated state may emphasize metabolic, protein, energy, connective-tissue, growth, and micronutrient support. An ovulatory-associated state may emphasize antioxidant, mitochondrial, cellular-defense, extracellular-matrix, tissue-remodeling, skin, or metabolic support. A luteal-associated state may emphasize neurotransmitter, relaxation/sleep, digestive/microbiome, mineral, metabolic, and recovery support.
Compositionally Distinct Formulations
At least two formulations are compositionally distinct when they differ in one or more of ingredient identity, functional ingredient category, amount, concentration, ratio, dose, dosage form, timing, frequency, or combinations thereof. A common base may be present while state-specific categories, ingredients, or amounts change.
Administration and HR+-Safe Embodiments
Formulations may be powders, gels, tablets, capsules, softgels, sachets, liquids, beverages, foods, or other orally ingestible forms. Administration may follow a calendar schedule or be dynamically adjusted according to the determined state. In certain embodiments, compositions are formulated without exogenous hormones or ingredients selected to mimic estrogen or progesterone and may be free of phytoestrogenic or progesterone-modulating botanicals.
PROPHETIC EXAMPLES
Example 1 — Calendar-Based Protocol
Menstrual onset identifies a first state. A first formulation emphasizes mineral restoration, hematopoietic support, inflammatory-response support, and recovery. A second emphasizes metabolic, protein, energy, and connective-tissue support. A third emphasizes antioxidant, mitochondrial, cellular-defense, and tissue-remodeling support. A fourth emphasizes neurotransmitter, relaxation, digestive, metabolic, and recovery support. Direct hormone measurement is not required.
Example 2 — Dynamically Determined State
A current state is inferred using menstrual onset, historical cycle patterns, wearable-derived data, symptoms, and biomarkers. The state determines nutritional priorities and functional ingredient categories. When the state changes, formulation, dose, or timing changes accordingly.
Example 3 — Functional Substitution
One implementation uses a first magnesium source for a phase-specific mineral-support function. Another substitutes a different bioavailable magnesium source while preserving substantially the same phase-specific nutritional role. The mapping from state to physiological priority to mineral-support category remains.
CLAIMS
1. A method of providing differentiated nutritional support across a plurality of changing female endocrine-associated physiological states, comprising: determining a current state from the plurality; associating the current state with one or more physiological environments; determining, based on the physiological environments, one or more nutritional support priorities; selecting, based on the priorities, one or more functional ingredient categories; and selecting or administering a nutritional composition corresponding to the current state, wherein the composition is compositionally distinct from a nutritional composition corresponding to at least one other state of the plurality.
2. The method of claim 1, wherein the current state is determined using at least one of calendar timing, menstrual onset, cycle history, symptoms, user-reported information, historical patterns, biomarkers, wearable-derived information, laboratory measurements, algorithmic inference, hormonal measurements, or combinations thereof.
3. The method of claim 1, wherein direct hormone measurement is not required.
4. The method of claim 1, wherein the plurality comprises at least three changing states within a female endocrine cycle.
5. The method of claim 1, wherein the plurality includes menstrual-associated, follicular-associated, ovulatory-associated, and luteal-associated states.
6. The method of claim 1, wherein the composition differs by at least one of ingredient identity, functional ingredient category, amount, concentration, ratio, dose, dosage form, timing, or frequency.
7. The method of claim 1, wherein a functional ingredient category is provided by any of a plurality of ingredients capable of providing substantially the same nutritional function for the current state.
8. The method of claim 1, wherein a first state emphasizes mineral restoration, hematopoietic support, or inflammatory-response support; a second emphasizes metabolic, protein, connective-tissue, or energy support; a third emphasizes antioxidant, mitochondrial, cellular-defense, or tissue-remodeling support; and a fourth emphasizes neurotransmitter, digestive, relaxation, sleep, metabolic, or recovery support.
9. A phase-aligned nutritional system comprising: a plurality of compositionally distinct orally ingestible nutritional compositions corresponding to a plurality of changing female endocrine-associated physiological states; and instructions or a control system configured to cause selection or administration of a respective composition according to a determined current state; wherein each respective composition is formulated according to a mapping comprising the corresponding state, an associated physiological environment, one or more nutritional support priorities, and one or more functional ingredient categories.
10. The system of claim 9, wherein the plurality is not limited to a fixed 28-day administration schedule.
11. The system of claim 9, wherein at least one state boundary is dynamically determined from physiological, historical, wearable-derived, biomarker, laboratory, user-reported, or algorithmically inferred information.
12. The system of claim 9, wherein at least two compositions share a common base and differ by at least one functional ingredient category, ingredient, amount, dose, or ratio.
13. The system of claim 9, wherein each composition is free of exogenous hormones and ingredients selected for the purpose of mimicking estrogen or progesterone.
14. A method of designing a multi-state female nutritional protocol, comprising: identifying a plurality of changing endocrine-associated physiological states; for each state, identifying a physiological environment associated with the state; translating the physiological environment into nutritional support priorities; mapping the priorities to functional ingredient categories; and defining a plurality of compositionally distinct nutritional formulations for administration across the plurality of states based on the mapped functional ingredient categories.
15. The method of claim 14, wherein the functional ingredient categories are defined independently of a specific ingredient identity.
16. The method of claim 14, wherein a first ingredient in a functional ingredient category is replaceable by a second ingredient that provides substantially the same nutritional function for the corresponding state.
17. A kit comprising a plurality of containers holding compositionally distinct nutritional formulations corresponding to multiple changing female endocrine-associated physiological states, and instructions identifying a state-associated administration sequence.
18. A computer-implemented method comprising: receiving information indicative of a current female endocrine-associated physiological state; selecting nutritional support priorities associated with the current state; selecting functional ingredient categories mapped to the priorities; and outputting an instruction identifying a compositionally differentiated nutritional formulation, dose, or timing corresponding to the current state.
19. The method of claim 18, wherein the information indicative of the current state excludes direct hormone measurements.
20. A plurality of orally ingestible nutritional compositions for sequential administration across multiple changing female endocrine-associated physiological states, wherein at least two compositions differ in functional nutritional emphasis corresponding to different physiological environments associated with respective states.
ABSTRACT
A phase-aligned nutritional mapping system provides differentiated nutritional support across multiple changing female endocrine-associated physiological states. A current state is determined using calendar, menstrual, historical, symptomatic, biomarker, wearable, laboratory, algorithmic, hormonal, or other information. The state is associated with a physiological environment, which is translated into nutritional support priorities and functional ingredient categories. A nutritional formulation, dose, or timing corresponding to the state is selected or administered, with at least two formulations being compositionally distinct. Functional ingredient categories permit different ingredients to provide substantially the same state-specific nutritional function. The system may operate without direct hormone measurement and is not limited to exactly four formulations or a fixed 28-day cycle.
COUNSEL REVIEW ITEMS
• Insert exact provisional application number and filing date.
• Audit every mapping and functional-category claim for priority support versus later-added material.
• Evaluate whether the mapping architecture belongs in this application, a continuation/CIP, or a separate family.
• Evaluate restriction risk among method, system, kit, software, and composition claim families.
• Preserve narrower HR+-safe claims without making hormone-neutral limitations mandatory in the broadest claims.